GlassScriptPhysician profile
Tasneem A Bholat
NPI 1114151271
$3,365.03
in general payments reported to CMS, 2019-2025
25 companies · $275 in 2025
The $275 reported for 2025 was more than what 82% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $403 · 2021: $670 · 2022: $679 · 2023: $436 · 2024: $390 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $677.14 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $381.49 | 2019-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $369.86 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $326.01 | 2019-2024 | Dificid |
| Abiomed | $276.55 | 2023-2025 | Impella |
| Shionogi INC | $208.89 | 2020-2024 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $184.72 | 2019-2021 | |
| Pfizer INC. | $180.93 | 2019-2023 | |
| Astellas Pharma US INC | $134.94 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.98 | 2021-2022 | |
| Allergan, INC. | $82.09 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.32 | 2025 | Lifevest |
| Gilead Sciences, INC. | $46.93 | 2024 | Veklury |
| Verona Pharma, INC. | $46.14 | 2025 | Ohtuvayre |
| Medtronic Vascular, INC. | $37.11 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.99 | 2022-2023 | Teflaro |
| Biomerieux INC | $27.52 | 2023 | Nephrocheck Liquid Control Kit |
| Kci USA, INC. | $26.27 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $24.69 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.65 | 2023 | Xifaxan |
| Aimmune Therapeutics, INC. | $23.01 | 2024 | |
| Cytovale, INC. | $21.26 | 2025 | |
| Paratek Pharmaceuticals, INC. | $17.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasneem Bholat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.